

A role for the P2X₇ receptor in the immune
response to *Toxoplasma gondii*

by

Michael Lees

BSc (Hons) (UTS)

A thesis submitted for the degree of Doctor of Philosophy

Institute for the Biotechnology of Infectious Diseases

University of Technology, Sydney,

Australia

2009

Certificate

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Michael Lees

Acknowledgements

I started my PhD in 2005, under the early supervision of Dr Nicky Boulter and Prof Nick Smith. After Dr Boulter departed for a new job, my supervision fell to the hands of Prof Nick Smith and Dr Kate Miller. I whole heartedly thank my supervisors for all the help, support and input they have given me throughout the course of my PhD, with brain storming, lab work and reviewing my thesis. I have been fortunate to have such brilliant mentors.

My love of science began with my father, Mr Stephen Lees. His love of nature and a desire to understand his world, has rubbed off on me more than I am sure he realises. My Mother, Mrs Jennifer Lees, shaped me into the person I am. Mum, your strength and resolve with all aspects of your own life inspired me to go to university and undertake this PhD. Without the love and support I have received from you both, I would not have arrived where I am today. My moral values, scientific inspiration and loyalty to family and friends come from you, Dad and Mum. To Kylie, thank you for holding me together and loving me no matter what. Whatever comes next, I know we're ready for it.

I thank Prof James Wiley and Dr Steve Fuller for being supportive and productive collaborators and making the initial clinical observations with three toxoplasmosis patients which led to the beginning of this project.

During my PhD, it was a privilege spending three months at the University of Chicago, working in the laboratory of Prof Rima McLeod with samples from the NCCCTS. In collaboration with Prof Jennie Blackwell and Dr Sarra Jamieson, all subjects in the NCCCTS had previously been genotyped at eight P2X₇ receptor loci in order to conduct association testing for P2X₇ polymorphisms and congenital toxoplasmosis.

I sincerely thank Prof Rima McLeod, Dr Evan McLeod, Dr William Witola and Mr Ernest Mui for welcoming me to Chicago and helping me to realise my potential. I also thank Prof Jennie Blackwell and Dr Sarra Jamieson for making P2X₇ receptor genotyping and association testing data of the NCCCTS and EMSCOT available to me.

I also thank IBID and the Faculty of Science for my PhD scholarship and travel funding assistance, the ARC/NHMRC Research Network for Parasitology and the Australian Society for Parasitology for conference and travel funding assistance.

Very many of my friends deserve my gratitude. I thank Miss Amanda Hudson, Dr Catherine James, Mr Rowan Ikin, Dr Marilyn Katrib, Dr Jonathan Lowther, Dr Robert Walker and Miss Alana Zakrzewski for their friendship, input and regular help with my lab work. My friends are of course a very important part of my life, evidenced by the quality time we spent together, sensibly discussing the finer points of science and the arts over one (and never more than one) glass of wine or beer. Thank you for helping me in so many ways throughout my PhD, but particularly with maintaining my threadbare sanity.

Finally, I thank my long term friend, Sam, who was with me at the start but unfortunately left us for greener pastures before I could show him this thesis. ♥

To my wonderful parents.

Table of contents

CERTIFICATE	I
ACKNOWLEDGEMENTS	II
DEDICATION	IV
TABLE OF CONTENTS	V
LIST OF FIGURES AND TABLES.....	VIII
ABBREVIATIONS	X
ABSTRACT	XIII
CHAPTER 1 – INTRODUCTION.....	1
1.1 – <i>Toxoplasma gondii</i>	1
1.2 – <i>Infection and disease</i>	4
1.3 – <i>Treatment and vaccines</i>	5
1.4 – <i>Host cell invasion</i>	7
1.5 – <i>Immune response to T. gondii</i>	9
1.6 – <i>Immune evasion by T. gondii</i>	14
1.7 – <i>Clinical toxoplasmosis cases at Nepean Hospital</i>	18
1.8 – <i>Purinergic P2 receptors</i>	21
1.9 – <i>P2X₇ receptor</i>	25
1.10 – <i>P2X₇ receptor and intracellular bacteria</i>	31
1.11 – <i>P2X₇ receptor and intracellular parasites</i>	35
1.12 – <i>Project aim</i>	37
1.13 – <i>Objectives</i>	38
CHAPTER 2 – GENERAL MATERIALS AND METHODS.....	39
2.1 - MATERIALS.....	39
2.2 – METHODS	43
2.2.1 – <i>Ethics</i>	43
2.2.2 – <i>Statistical analysis</i>	44
2.2.3 – <i>In vitro tissue culture</i>	44
2.2.4 – <i>T. gondii tachyzoite culture – Vero cells</i>	44
2.2.5 – <i>T. gondii tachyzoite culture – HFF cells</i>	45

2.2.6 – RAW 264.7 cell culture	45
2.2.7 – Murine bone marrow macrophage culture.....	46
2.2.8 – Human PBMC culture – Method 1.....	46
2.2.9 – Human PBMC Culture – Method 2	47
2.2.10 – P2X ₇ receptor function assay	48
CHAPTER 3 – T. GONDII VIABILITY AND REPLICATION ASSAYS – METHOD	
DEVELOPMENT	50
3.1 - INTRODUCTION	50
3.2 – METHODS AND RESULTS	53
3.2.1 – Microplate cytometry replication assay.....	53
3.2.2 – Flow cytometry viability assay	56
3.2.3 – Comparative validation of flow cytometry viability assay	60
3.3 – DISCUSSION	64
CHAPTER 4 – HUMAN P2X₇ RECEPTOR INVESTIGATION	68
4.1 – INTRODUCTION.....	68
4.2 – METHODS AND RESULTS	70
4.2.1 – RH <i>T. gondii</i> viability following human P2X ₇ receptor activation	70
4.2.2 – RH <i>T. gondii</i> burden following polymorphic human P2X ₇ receptor activation	74
4.3 – DISCUSSION	80
CHAPTER 5 – IN VITRO MURINE P2X₇ RECEPTOR INVESTIGATION	83
5.1 – INTRODUCTION.....	83
5.2 – METHODS AND RESULTS	84
5.2.1 – P2X ₇ receptor investigation with RAW 264.7 cells.....	84
5.2.2 – P2X ₇ receptor investigation with murine BMM	91
5.3 – DISCUSSION	94
CHAPTER 6 – IN VIVO MURINE P2X₇ RECEPTOR INVESTIGATION	100
6.1 – INTRODUCTION.....	100
6.2 – METHODS AND RESULTS	100
6.2.1 – Murine infection with RH <i>T. gondii</i> – parasite burden	100

6.2.2 – Murine infection with RH <i>T. gondii</i> – inflammatory cytokine analysis	102
6.3 – DISCUSSION	114
CHAPTER 7 – GENERAL DISCUSSION	118
7.1 – KEY FINDINGS	118
7.2 – FUTURE DIRECTIONS	124
7.3 – FINAL CONCLUSION	127
BIBLIOGRAPHY	129

List of figures and tables

CHAPTER 1 – INTRODUCTION.....	1
<i>Figure 1.1 – Lifecycle of Toxoplasma gondii (Ferguson, 2002).</i>	2
<i>Figure 1.2 – Summary of the innate immune response to T. gondii.</i>	10
<i>Table 1.1 – Immunological investigation of toxoplasmosis subjects.</i>	19
<i>Figure 1.3 – P2X₇ receptor function of toxoplasmosis subjects.</i>	20
<i>Table 1.2 – P2X₇ receptor genotype of toxoplasmosis subjects.</i>	21
<i>Figure 1.4 – Membrane topology of P2X receptors.</i>	24
CHAPTER 2 – GENERAL MATERIALS AND METHODS.....	39
CHAPTER 3 – T. GONDII VIABILITY AND REPLICATION ASSAYS – METHOD	
DEVELOPMENT	50
<i>Figure 3.1 – YFP RH T. gondii fluorescence image.</i>	55
<i>Figure 3.2 – Validation of microplate cytometry T. gondii replication assay.</i>	56
<i>Figure 3.3 – Typical density plots obtained from flow cytometry T. gondii viability</i> <i>assay.....</i>	<i>59</i>
<i>Figure 3.4 – Fluorescence microscopy assessment of T. gondii tachyzoite viability.</i> <i>.....</i>	<i>62</i>
<i>Figure 3.5 – Comparison of T. gondii tachyzoite viability assays.....</i>	<i>63</i>
CHAPTER 4 – HUMAN P2X₇ RECEPTOR INVESTIGATION	68
<i>Figure 4.1 – P2X₇ receptor function of a normal/control donor.</i>	71
<i>Figure 4.2 – RH T. gondii viability and burden following human P2X₇ receptor</i> <i>activation.</i>	<i>73</i>
<i>Figure 4.3 – RH T. gondii burden in ATP-treated cells with functional P2X₇</i> <i>receptors.</i>	<i>76</i>
<i>Figure 4.4 – RH T. gondii burden in ATP-treated cells with 1513C P2X₇ receptor</i> <i>polymorphism.....</i>	<i>77</i>
<i>Figure 4.5 – Percent reduction of parasite burden by P2X₇ receptor genotypes 1 –</i> <i>3.....</i>	<i>79</i>

CHAPTER 5 – IN VITRO MURINE P2X₇ RECEPTOR INVESTIGATION	83
<i>Figure 5.1 – RAW 264.7 cell P2X₇ receptor expression.</i>	<i>86</i>
<i>Figure 5.2 – P2X₇ receptor function of RAW 264.7 cells.</i>	<i>87</i>
<i>Figure 5.3 – RH T. gondii viability following P2X₇ receptor activation of RAW 264.7 cells.....</i>	<i>90</i>
<i>Figure 5.4 – P2X₇ receptor function of murine BMM.</i>	<i>92</i>
<i>Figure 5.5 – RH T. gondii viability following P2X₇ receptor activation of murine BMM.....</i>	<i>94</i>
CHAPTER 6 – IN VIVO MURINE P2X₇ RECEPTOR INVESTIGATION	100
<i>Figure 6.1 – Parasite burden at site of infection in RH T. gondii infected mice. ...</i>	<i>102</i>
<i>Figure 6.2 – Serum IL-12p70 concentration in RH T. gondii infected mice.</i>	<i>105</i>
<i>Figure 6.3 – Serum IFN-γ concentration in RH T. gondii infected mice.</i>	<i>106</i>
<i>Figure 6.4 – Serum MCP-1 concentration in RH T. gondii infected mice.</i>	<i>107</i>
<i>Figure 6.5 – Serum IL-6 concentration in RH T. gondii infected mice.</i>	<i>108</i>
<i>Figure 6.6 – Serum TNF concentration in RH T. gondii infected mice.</i>	<i>109</i>
<i>Figure 6.7 – Serum IL-10 concentration in RH T. gondii infected mice.</i>	<i>110</i>
<i>Figure 6.8 – Serum IL-1β concentration in RH T. gondii infected mice.</i>	<i>112</i>
<i>Figure 6.9 – Serum NO concentration in RH T. gondii infected mice.</i>	<i>114</i>
CHAPTER 7 – GENERAL DISCUSSION	118
<i>Figure 7.1 – Downstream events following P2X₇ receptor activation.</i>	<i>120</i>
<i>Figure 7.2 – Apoptosis induced by P2X₇ receptor activation of RH T. gondii infected RAW 264.7 cells.....</i>	<i>123</i>
BIBLIOGRAPHY	129

Abbreviations

ADP	Adenosine diphosphate
AIDS	Acquired immunodeficiency syndrome
AMP	Adenosine monophosphate
ANOVA	Analysis of variance
APLT	Aminophospholipid translocase
ATCC	American type culture collection
ATP	Adenosine triphosphate
BBG	Brilliant blue G
BCG	Bacillus Calmette-Guérin
BMM	Bone marrow macrophage
BN-PAGE	Blue native polyacrylamide gel electrophoresis
BSA	Bovine serum albumin
BzATP	Benzoyl-benzoyl adenosine triphosphate
CBA	Cytometric bead array
CD	Cluster of differentiation
CFU	Colony forming units
CNS	Central nervous system
CTL	Cytotoxic T-lymphocyte
DAPI	4',6-diamidino-2-phenylindole
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
EMSCOT	European Multicentre Study on Congenital Toxoplasmosis
FACS	Fluorescence activated cell sorting
FBS	Foetal bovine serum
FITC	Fluorescein isothiocyanate
FSC	Forward scatter
FSW	FACS stain/wash solution
GM-CSF	Granulocyte macrophage-colony stimulating factor
HBSS	Hank's balanced salt solution

HEPA	High efficiency particulate air
HFF	Human foreskin fibroblast
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HSP	Heat shock protein
IFN	Interferon
IL	Interleukin
IMDM	Iscove's Modified Dulbecco's Medium
LPS	Lipopolysaccharide
MACS	Magnetically activated cell sorting
MAPK	Mitogen-activated protein kinase
M-CSF	Macrophage colony stimulating factor
MDM	Monocyte derived macrophage
MHC	Major histocompatibility complex
MOI	Multiplicity of infection
MyD88	Myeloid differentiation factor 88
NADPH	β -Nicotinamide adenine dinucleotide phosphate
NBS	Newborn bovine serum
NCCCTS	National Collaborative Chicago-based Congenital Toxoplasmosis Study
NEAA	Non-essential amino acids
NED	N-(1-naphthyl) ethylene diamine
NFAT	Nuclear factor of activated T-cells
NF- κ B	Nuclear factor- κ B
NIH	National Institutes of Health
NK	Natural killer
NO	Nitric oxide
NTP	Nucleotide triphosphate
oATP	Oxidised adenosine triphosphate
PBL	Peripheral blood lymphocyte
PBMC	Peripheral blood mononuclear cell
PBS	Phosphate buffered saline
PMA	Phorbol-12-myristate-13-acetate
PPADS	Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate
PS	Penicillin/streptomycin

PSF	Penicillin/streptomycin/fungicide
RNI	Reactive nitrogen intermediates
ROCK	Rho-effector kinase
ROI	Reactive oxygen intermediates
RPMI	Roswell Park Memorial Institute
SNP	Sodium nitroprusside
SSC	Side scatter
TCA	Trichloroacetic acid
TGF- β	Transforming growth factor- β
TNF	Tumour necrosis factor
TLR	Toll-like receptor
USB	Universal serial bus
UV	Ultraviolet
YFP	Yellow fluorescent protein

Abstract

The P2X₇ receptor is a membrane bound cation channel expressed mainly on the surface of immune cells such as macrophages, lymphocytes and dendritic cells. P2X₇ receptor expression is up-regulated in response to the cytokine, IFN- γ , which also plays an integral role in the immune response to *Toxoplasma gondii*. Activation of the P2X₇ receptor is achieved through prolonged exposure to > 100 μ M ATP, which may be released from a variety of cellular sources, including activated platelets and dead/dying/damaged cells (including cellular damage caused by intracellular pathogens). Various studies have already demonstrated the ability of P2X₇ receptor activation to kill intracellular *Mycobacterium* spp., and have also linked a defective P2X₇ receptor with tuberculosis in humans. P2X₇ receptor activation is also known to kill intracellular *Chlamydia* spp., and has also been implicated in the immune response to *Leishmania* spp.

The hypothesis for this PhD project was that activation of the P2X₇ receptor results in the killing of intracellular *T. gondii*. Furthermore, that a defective P2X₇ receptor gene interferes with the normal immune response to *T. gondii*, rendering an individual more susceptible to severe disease following infection with *T. gondii*. Therefore the specific aims for this PhD project were to:

1. Develop fast, reliable methods to assess the viability and replication of intracellular *T. gondii* tachyzoites *in vitro*;
2. Assess the effect of ATP stimulation of human and murine immune cells on the viability and/or replication of Type I (RH) tachyzoites of *T. gondii*;
3. Assess the effect of deficiencies in P2X₇ receptor activity on the ability of ATP to affect the viability and/or replication of Type I (RH) tachyzoites of *T. gondii*;
4. Assess the effect of deficiencies in P2X₇ receptor activity on the production of inflammatory cytokines and mediators in response to infection with Type I (RH) tachyzoites of *T. gondii*.

Prior to investigating the role of the P2X₇ receptor in the immune response to *T. gondii*, two assays were developed that facilitated the accurate measurement of intracellular *T. gondii* tachyzoite viability or burden/replication. The viability assay used flow

cytometry to quickly and accurately quantify intracellular *T. gondii* tachyzoite viability, whereas the burden/replication assay used microplate cytometry to quantify intracellular *T. gondii* tachyzoite burden in host cells available in extremely limited quantities.

The human P2X₇ receptor was first investigated through *in vitro* experiments aimed at elucidating a role for P2X₇ receptor activation in the human immune response to *T. gondii*. Initially, RH *T. gondii* strain tachyzoites were infected into monocyte-derived macrophages cultured from a donor with full P2X₇ receptor function. ATP treatment of these cells to activate the receptor significantly reduced the viability of intracellular RH *T. gondii* (measured by the flow cytometry assay) and also reduced the number of intracellular YFP expressing RH *T. gondii* (measured by the microplate cytometry assay). Monocyte-derived macrophages from subjects with wild-type and polymorphic P2X₇ receptor genes were then infected with YFP expressing RH *T. gondii*, treated with ATP and parasite numbers monitored by microplate cytometry. Cells from donors with a polymorphism resulting in a loss of P2X₇ receptor function were unable to reduce the number of intracellular parasites whereas cells from donors with a wild type gene or a polymorphism that did not result in a loss of P2X₇ receptor function were able to reduce intracellular parasite numbers after ATP treatment

To complement the human investigation, experiments involving the murine P2X₇ receptor began with an *in vitro* investigation into the role of P2X₇ receptor activation in the murine immune response to *T. gondii*. These experiments definitively confirmed that ATP induced killing of RH *T. gondii* occurs via P2X₇ receptor activation, and not any other purinergic receptor/effect of ATP treatment. Blocking activation of the P2X₇ receptor in the immortalised RAW 264.7 mouse macrophage-like cell line by pre-treatment with the P2X₇ receptor antagonist, oATP, showed a reduction in ATP-induced RH *T. gondii* killing. Similarly, ATP treatment of bone marrow-derived macrophages cultured from P2X₇ receptor knockout mice did not result in a significant reduction in intracellular RH *T. gondii* viability.

The murine P2X₇ receptor investigation concluded with *in vivo* experiments aimed at understanding the phenotype of RH *T. gondii* infection in P2X₇ receptor knockout mice. These experiments showed that lack of P2X₇ receptor expression was associated with lower parasite burden at the site of infection and decreased serum concentration of

cytokines responsible for promotion and regulation of the inflammatory immune response.

The experiments conducted throughout this PhD have aided in the understanding of the immune response to *T. gondii*. It was previously known that P2X₇ receptor activation was important in the immune response to *Mycobacterium* spp., *Chlamydia* spp. and *Leishmania* spp. The role of the P2X₇ receptor may now also be extended to include *T. gondii*.